Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Fiscal second quarter and six months ended September 30, 2022. Vistagen is a clinical-stage biopharmaceutical company developing PH94B and PH10 nasal sprays and AV-101; it had no approved products or recurring product-sales revenue.
Financial position and results
| Metric | Three months ended September 30, 2022 | Six months ended September 30, 2022 |
|---|---|---|
| Revenue | $(0.9) million | $(0.6) million |
| Research and development | $12.9 million | $28.2 million |
| General and administrative | $3.7 million | $8.5 million |
| Net loss | $17.5 million | $37.3 million |
| Net loss per common share | $0.08 | $0.18 |
For comparison, the prior-year quarter had $0.4 million revenue and a $12.8 million net loss; the prior-year six-month period had $0.7 million revenue and a $20.5 million net loss. Six-month R&D expense rose from $15.4 million and G&A from $5.9 million. The filing does not provide a meaningful product gross margin; revenue is sublicense revenue, not product sales.
- Cash and liquidity: Cash and equivalents were $35.3 million at September 30, down from $68.1 million at March 31, 2022. Current assets were $36.9 million and current liabilities $6.0 million.
- Cash flow: Operating cash use was $32.3 million for the six months, versus $17.6 million a year earlier. Investing cash use was $0.2 million; financing cash use was $0.3 million. Cash declined by $32.8 million.
- Debt and obligations: Notes payable were $0.73 million, relating to insurance-premium financing. Operating lease liabilities totaled $2.83 million; financing lease obligations were approximately $0.01 million.
- Equity: Stockholders’ equity was $29.6 million, down from $64.7 million at March 31. Accumulated deficit was $304.9 million. The company reported 206.8 million common shares outstanding as of November 9, 2022.
Material changes and unusual items
- PALISADE-1, a Phase 3 PH94B study in social anxiety disorder (SAD), failed to meet its primary efficacy endpoint. Safety and tolerability were described as favorable.
- After the PALISADE-1 result, Vistagen extended its estimated period to complete services under the AffaMed PH94B agreement from mid-2024 to mid-2027. This estimate change caused a cumulative catch-up adjustment, reducing reported sublicense revenue by $0.9 million in the quarter and $0.6 million for the six months. It also reversed some related contract-acquisition-cost amortization. These are accounting adjustments; the filing does not describe them as cash repayments.
- Higher six-month R&D spending primarily reflected the PH94B PALISADE program, the PH94B AjDA study, and PH94B/PH10 manufacturing and regulatory work. G&A growth included pre-commercialization work, insurance, investor relations, and professional services.
- The company incurred approximately $0.3 million of professional fees for a potential credit facility that it abandoned after the PALISADE-1 result. No additional ATM stock sales were reported from October 2021 through the report date.
Outlook, risks, and contingencies
- Going concern and funding: Management said the $35.3 million cash balance was probably insufficient for planned operations for the 12 months following issuance of the financial statements, raising substantial doubt about the company’s ability to continue as a going concern. It expects continued losses and negative operating cash flows and may seek equity or debt financing, grants, or collaborations; availability and terms are uncertain.
- Development plans: Following an independent interim review, biostatisticians recommended continuing PALISADE-2. The company was preparing to restart enrollment and stated in MD&A it expected to resume in the first quarter of calendar 2023, aiming for 208 subjects. It also planned to discuss the next PH94B Phase 3 step with FDA. Recruitment for the PALISADE open-label safety study ended.
- Enrollment in the PH94B exploratory AjDA study was complete, with top-line results anticipated in the first calendar quarter of 2023. A U.S. PH10 IND had been submitted; the company planned a small Phase 1 study before year-end 2022, subject to FDA clearance. The AV-101/probenecid Phase 1B interaction study was ongoing.
- Management expected PH94B R&D project spending to fall in the near term after PALISADE-1 completion and the open-label study’s conclusion, then increase with PALISADE-2; PH10 Phase 1 work was expected to add costs. No quantified financial guidance was provided.
- Nasdaq notified the company in September that it did not meet the $1.00 minimum bid-price requirement. The initial compliance period ran through March 6, 2023; failure to regain compliance could lead to delisting and impair capital raising.
- Other key risks include clinical and regulatory failure, reliance on third-party manufacturers and trial operators, potential COVID-related supply or trial disruptions, and the need for substantial additional capital. Legal proceedings: none reported. Management reported disclosure controls were effective.
Investor facts to verify
- Cash runway assumptions and the timing, size, dilution, and availability of future financing.
- PALISADE-2 restart, completion, results, and FDA alignment on the next PH94B Phase 3 plan.
- Upcoming AjDA results and FDA clearance and execution of the PH10 Phase 1 study.
- Effects of the revised AffaMed performance-period estimate on future reported revenue and cash receipts; milestone and royalty payments remain contingent.
- Nasdaq bid-price compliance status and any resulting listing or capital-market actions.